Drug intelligence / Profile preview

autologous bone marrow and allogeneic umbilical cord mesenchymal stem cells + platelet-rich plasma

Development stage
Unknown
Lead developer
Van Hanh General Hospital
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

This investigational cell therapy, developed by Van Hanh General Hospital in Vietnam, is a combination treatment for type 1 diabetes mellitus. It utilizes two sources of mesenchymal stem cells (MSCs)—autologous bone marrow-derived and allogeneic umbilical cord-derived—which are administered alongside activated platelet-rich plasma (PRP). The therapy is designed to leverage the immunomodulatory and regenerative capabilities of MSCs to halt the autoimmune destruction of insulin-producing beta cells and promote the restoration of pancreatic function. It is currently being evaluated in Phase 1/2 clinical trials (NCT04061746).

Other names
MSC and PRPMSC transplantation for Type 1 Diabetes Mellitusmesenchymal stem cells-Van Hanh General Hospital-type 1 diabetes mellitus

Beyond the preview

Go deeper on autologous bone marrow and allogeneic umbilical cord mesenchymal stem cells + platelet-rich plasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bone marrow and allogeneic umbilical cord mesenchymal stem cells + platelet-rich plasma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call